According to him, the first group of elderly volunteers included 28 people.
“The first group of participants was screened last Thursday (October 22 -
RT
), was hospitalized on Sunday, and on October 28 she received a dose of the vaccine,” Lomakin said in an interview with the Izvestia newspaper.
He noted that in a study among young people in the first 24-49 hours after the first dose of vaccine, a pre-influenza state and fever were observed among the side effects.
"None of the participants in the studies of the older age group from those who received the vaccine on October 28 had these reactions ... We did not notice any manifestations ... No skin reactions, no fever, no premorbid (preinfluenza) background", - Lomakin emphasized.
He added that this may be due to the fact that the immune system of the elderly is a little suppressed, and they do not respond so brightly to the vaccine.
The study leader also said that trial participants are hospitalized twice - after receiving the first dose of vaccine for six days and two weeks later for three days for the second dose of vaccine.
“Within six months, these patients are checked: they will come to the hospital, they will be contacted by phone.
They will take different blood tests (a very large panel) in order to clarify some issues both from the point of view of safety and from the scientific side, ”added Lomakin.
A total of 110 people are planned to be included in the study on risk groups.
Persons with cancer, viral hepatitis or allergic reactions, patients receiving cancer drugs or immunosuppressive therapy, as well as elderly people who have suffered an acute heart attack or acute stroke within a year cannot participate in the study.
At the end of September, the Gamaleya Institute launched clinical trials of the Sputnik V vaccine on risk groups.
Inna Dolzhikova, head of the laboratory of the State Collection of Viruses at the Gamaleya Center, spoke with URA.RU about the Sputnik V vaccine